Key Highlights
- 30 days: how quickly the FDA granted Breakthrough Device Designation to HeartBeam (NASDAQ:BEAT) for at-home heart attack assessment, announced October 5, 2026, well ahead of the agency's 60-day statutory review period for such requests, according to the company.
- 134 patients: the size of the ALIGN-ACS pilot study, plus proof-of-concept data from the 2025 American Heart Association Scientific Sessions, that supported the designation, though the release gave no sensitivity or specificity figures for heart attack detection.
- About 398 million shares: Monday's trading Volume as HeartBeam (NASDAQ:BEAT) rose roughly 50 percent to near USD 0.65, per published market data, a price below the USD 1.00 minimum bid level that Nasdaq expects for continued listing.
- Coming months: the timeline HeartBeam gives for seeking FDA alignment on a multicenter pivotal study design, with patient enrollment expected shortly afterward and no date yet set for any Marketing clearance filing for heart attack assessment.
What the FDA Granted
HeartBeam said on October 5, 2026 that the FDA granted Breakthrough Device Designation to the HeartBeam System as a tool for assessing potential heart attacks at home. Its 3D ECG captures the heart's electrical signals from three non-coplanar dimensions, letting physicians review ECG information remotely when symptoms start. The agency decided within 30 days of the request. The same platform already holds FDA clearance for arrhythmia assessment, from December 2024 for the 3D ECG and December 2025 for 12-lead ECG synthesis software.
What Breakthrough Status Does Not Do
The designation provides prioritized FDA interaction and review during development. It does not authorize the heart attack use, and it is not a Medicare coverage decision, although it is a prerequisite for certain expedited Medicare pathways. HeartBeam expects to seek FDA alignment on a multicenter pivotal study design in the coming months and to start enrollment shortly afterward. Updates from ALIGN-ACS at a cardiology meeting and the HEADSTART-ACS study are expected in the coming weeks.
Price, Volume and Risk
Shares rose about 50 percent on Monday to near USD 0.65 on roughly 398 million shares traded, per published market data. The release gave no sensitivity or specificity figures for heart attack detection, so accuracy remains unproven. A pivotal study must still be agreed, run and submitted, which takes time and capital. Trading below USD 1.00 can also draw a Nasdaq minimum bid notice if it persists, and companies in that position often raise money by issuing shares.
Where Things Stand
It is worth watching as a development-stage story, not as a near-term product. HeartBeam (NASDAQ:BEAT) has an unusually quick regulatory signal and an existing cleared platform, but the heart attack use still needs a pivotal study, FDA agreement and clearance. The stock's move reflects hope more than data, since no accuracy figures were released. Next catalysts are the ALIGN-ACS data update and HEADSTART-ACS news expected in coming weeks and FDA alignment on the pivotal design in coming months. The pivotal study is the real test of whether the technology works as described.






Please wait processing your request...